Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population

European Journal of Human Genetics

Volumn 15, Issue 10, 2007, Pages 1049-1053

  Liu, Baorui ^a   Wei, Jia ^a   Zou, Zhengyun ^a   Qian, Xiaoping ^a   Nakamura, Takahiro ^b   Zhang, Wei ^a   Ding, Yitao ^a   Feng, Jifeng ^c   Yu, Lixia ^a  

^a NANJING UNIVERSITY   (China)

^b RIKEN   (Japan)

^c JIANGSU CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GLUTATHIONE TRANSFERASE P1; NUCLEIC ACID BINDING PROTEIN; OXALIPLATIN; UNCLASSIFIED DRUG; X RAY REPAIR CROSS COMPLEMENTING GROUP 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CHINESE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG PROTEIN BINDING; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEASE PROTECTION ASSAY; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CHINA; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; SURVIVAL RATE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 34848912861     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201884     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z: Quality of life in patients with advanced gastric cancer: A randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006; 6: 274.
3. Sumpter K, Harper-Wynne C, Cunningham D et al: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-1983.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
5. Rosell R, Cecere F, Santarpia M, Reguart N, Thron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006; 6: 323-331.
6. Olaussen KA, Dunant A, Fouret P et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
7. Marsh S, McLeod HL: Cancer pharmacogenetics. Br J Cancer 2004; 90: 8-11.
8. Gurubhagavatula S, Liu G, Park S et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.
9. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC: ABCCS, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005; 4: 18.
10. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
11. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280.
12. Brem R, Hall J: XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005; 33: 2512-2520.
13. Nazarkina ZK, Khodyreva SN, Marsin S, Lavrik OI, Radicella JP: XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst) 2007; 6: 254-264.
14. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H: Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801-807.
15. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006; 54: 267-283.
16. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW: XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2384-2390.
17. Huang WY, Chow WH, Rothman N et al: Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis 2005; 26: 1354-1359.
18. Hirata H, Hinoda Y, Tanaka Y et al: Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 2007; 43: 231-237.
19. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006; 13: 1379-1385.
20. de las Penas R, Sanchez-Ronco M, Alberola V et al: Spanish Lung Cancer Group, Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668-675.
21. Bewick MA, Conlon MS, Lafrenie RM: Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006; 24: 5645-5651.
22. Wu X, Gu J, Wu TT et al: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 4: 3789-3798.
23. Ruzzo A, Graziano F, Kawakami K et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24: 1883-1891.
24. Park DJ Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658.
25. Ryu JS, Hong YC, Han HS et al: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
26. Isla D, Sarries C, Rosell R et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
27. Stoehlmacher J, Park DJ, Zhang W et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-354.
28. Xing D, Tan W, Wei Q, Lin D: Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 2002; 38: 123-129.
29. Yang G, Shu XO, Ruan ZX et al: Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103: 52-58
30. Goekkurt E, Hoehn S, Wolschke C et al: Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006; 94: 281-286.
31. Stoehlmacher J, Park DJ, Zhang W et al: Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-942.
32. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
33. Nishiyama M, Yamamoto W, Park JS et al: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620-2628.
34. Zhan M. Liu X: Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl) 1999; 112: 336-339.